drugset
drugset / Trial / NCT06375343

Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®

NCT06375343 ↗

Phase 1 Not yet recruiting 32 enrolled Laboratorios Sophia S.A de C.V.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the incidence of stinging after its administration, compared to Optive®.

Timeline

Start
2026-01-30
Primary completion
2027-01-30
Completion
2027-01-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carboxymethylcellulose Other / unclassified 0.5 % Other
Subject Glycerin Other / unclassified 0.2 % Other
Subject Glycerin Other / unclassified 0.9 % Other
Subject Polyethylene glycol 400 Unknown 0.5 % Other
Subject Propylene Glycol Small molecule 0.3 % Other

Indications

dry eye syndrome